No Data
Jazz Pharmaceuticals' (NASDAQ:JAZZ) Earnings Have Declined Over Five Years, Contributing to Shareholders 16% Loss
Truist Financial Maintains Jazz Pharmaceuticals(JAZZ.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Jazz Pharmaceuticals(JAZZ.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 51.9% and a total average return of 23.3%
Jazz Pharmaceuticals (JAZZ) Gets a Buy From Truist Financial
Jazz Pharmaceuticals Says Gastric Cancer Therapy Shows Promise in Mid-Stage Study
Express News | Jazz Pharmaceuticals PLC - Zanidatamab Plus Chemotherapy Shows Manageable Safety Profile
Stock Moves Reflect Downgrade for US Economic Growth Outlook - Goldman